Skip to content
★ Sign in to follow
JB
Total declarations
78
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (26 ops.)
€8.6M

Latest filing published 02 Oct 2020 for Amicus Therapeutics, INC., €7,937.

Filing timeline

BuySale
Jay Barth

Insider track record

Disclosed buys
0
Disclosed sells
26
Signal history

Jay Barth: trading record in brief

Jay Barth appears in our data through filings on Amicus Therapeutics, Inc. shares, published by SEC (Form 4). In total, 78 filings cover trades dated from 10 April 2014 to 30 September 2020.

Every open-market trade on record is a sale: 26 sales worth €8.6M. Outside the open market, there are 20 share grants and 31 option exercises. So far in 2020, the count stands at no purchases and 13 sales.

The record was last updated on 2 October 2020 with an option exercise (€7,937) in Amicus Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Jay Barth

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations73 total
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    9,307 USD11SEC
    4,064 shares@ US$2.290.1% of flowCommon StockSEC:0001209191-20-053165:0
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    58,951 USD26SEC
    4,064 shares@ US$14.50570.5% of flowCommon StockSEC:0001209191-20-053165:1
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    175,375 USD11SEC
    28,750 shares@ US$6.101.5% of flowCommon StockSEC:0001209191-20-049131:0
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    423,775 USD29SEC
    28,750 shares@ US$14.743.7% of flowCommon StockSEC:0001209191-20-049131:1
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    183,000 USD11SEC
    30,000 shares@ US$6.101.6% of flowCommon StockSEC:0001209191-20-044005:0
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    451,500 USD29SEC
    30,000 shares@ US$15.054.0% of flowCommon StockSEC:0001209191-20-044005:1
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    99,523 USD11SEC
    11,559 shares@ US$8.610.9% of flowCommon StockSEC:0001209191-20-042311:0
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    79,916 USD11SEC
    8,850 shares@ US$9.030.7% of flowCommon StockSEC:0001209191-20-042311:1
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    61,666 USD11SEC
    6,142 shares@ US$10.040.6% of flowCommon StockSEC:0001209191-20-042311:2
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    219,763 USD11SEC
    17,896 shares@ US$12.282.0% of flowCommon StockSEC:0001209191-20-042311:3
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    707,596 USD30SEC
    44,447 shares@ US$15.926.5% of flowCommon StockSEC:0001209191-20-042311:4
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    147,965 USD11SEC
    28,843 shares@ US$5.131.4% of flowCommon StockSEC:0001209191-20-042311:5
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    451,393 USD29SEC
    28,843 shares@ US$15.654.1% of flowCommon StockSEC:0001209191-20-042311:6
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    443,682 USD11SEC
    51,531 shares@ US$8.614.1% of flowCommon StockSEC:0001209191-20-042033:0
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    583,347 USD12SEC
    64,601 shares@ US$9.035.4% of flowCommon StockSEC:0001209191-20-042033:1
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    128,552 USD11SEC
    12,804 shares@ US$10.041.2% of flowCommon StockSEC:0001209191-20-042033:2
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    614,639 USD12SEC
    50,052 shares@ US$12.285.7% of flowCommon StockSEC:0001209191-20-042033:3
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    3M USD32SEC
    178,988 shares@ US$15.9026.2% of flowCommon StockSEC:0001209191-20-042033:4
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    145,595 USD11SEC
    16,910 shares@ US$8.611.3% of flowCommon StockSEC:0001209191-20-042033:5
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    149,437 USD11SEC
    16,549 shares@ US$9.031.4% of flowCommon StockSEC:0001209191-20-042033:6
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    86,334 USD11SEC
    8,599 shares@ US$10.040.8% of flowCommon StockSEC:0001209191-20-042033:7
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    270,799 USD11SEC
    22,052 shares@ US$12.282.5% of flowCommon StockSEC:0001209191-20-042033:8
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    1M USD30SEC
    64,110 shares@ US$15.929.3% of flowCommon StockSEC:0001209191-20-042033:9
  • ◇
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    153,900 USD11SEC
    30,000 shares@ US$5.131.4% of flowCommon StockSEC:0001209191-20-039926:0
  • ▼
    Chief Medical OfficerExecutivesAmicus Therapeutics, Inc.
    465,195 USD29SEC
    30,000 shares@ US$15.50654.3% of flowCommon StockSEC:0001209191-20-039926:1

25 of 73 declarations